Drug Profile
Research programme: next generation neuroprotectants - Renovis
Latest Information Update: 01 May 2007
Price :
$50
*
At a glance
- Originator Renovis
- Class
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS trauma; Stroke
Most Recent Events
- 07 Jun 2005 This programme is still in active development
- 26 May 2004 Preclinical trials in CNS trauma in USA (PO)
- 26 May 2004 Preclinical trials in Stroke in USA (PO)